Biomedical company listed on the OTC market (current symbol AESO), requires funding to:
- Launch a new consumer range of health and wellness products commencing with a unique anti-anxiety formula; and
- Complete medical AI-based diagnostic products on the doorstep of FDA application (within 12 months).
1. Early Revenue Opportunity - Unique Wellness Products Ready for Sale
AESO has a comprehensive marketing program to launch a range of nutraceutical products commencing with a unique anti-anxiety formula. The program includes direct to consumer marketing, infomercials, digital and social media, radio and print media. We have a very experienced marketing team lead by a "direct-to-consumer" industry veteran.
The unique anti-anxiety formula offers benefits with respect to mood, anxiety, libido, sleep, energy and focus among many others derived from generations of Natural and Allopathic medical teachings. It was created and "Claim Substantiated" during an ongoing dialogue with David Anderson MD, a highly respected U.S. medical school senior research scientist and physician consultant familiar with natural products in general and more specifically, natural products that have been designed to nutritionally address the symptoms of anxiety, depression, low energy, sleep disturbances and cognitive dysfunction.
The unique anti-anxiety formula will appeal to individuals who are looking to naturally and nutritionally support the body’s inherent abilities to:
- respond to symptoms associated with depression and overly anxious moods;
- cope with the negative effects of stress, including decreased cognitive function, decreased memory and decreased focus leading to “Brain Fog”.
- balance the hormones that affect stress;
- address fatigue in order to attain optimal levels of energy and performance;
- support good quality and durable sleep; and
- support relaxation and feelings of wellness and tranquillity.
The Company also has a pipeline of new formulas' including:
- Anti-anxiety formula for pets.
- Male and female potency for increased sexual performance.
- Auto-immune enhancer to help guard against viruses.
- Weight loss formula.
2. AI-based Medical Diagnostic Technologies at Doorstep of FDA.
AESO also has a medical division that has developed artificial intelligence-based medical diagnostic technologies to quickly and accurately diagnose:
- blood clot in the lungs (Pulmonary Embolisms); and
- the severity of Cystic Fibrosis for better treatment options.
Funding is required to complete the FINAL validation phase for an FDA application (within 12 months) for both technologies.
The Company will commence its commercialisation strategies immediately upon funding (i.e. during the final validation stage) to license the technology to - or collaborate with - major manufacturers of MRI machines (e.g. Siemens, Philips and GE) and pharmaceutical companies.
Exit Opportunity
Success in both or either of the Company's divisions (i.e. its wellness products or its clinical division) will significantly increase the Company's valuation, at which time an up-listing to NASDAQ will be considered. The Company has many press-release opportunities scheduled in order to keep the market informed and ensure its valuation. This will present an opportunity to exit for those shareholders wishing to do so.
Ready to Ask For Funding for your company?
Post a Funding Request